alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# C_2014395EN.01006801.xml

| 10.11.2014 | EN | Official Journal of the European Union | C 395/68 |
| --- | --- | --- | --- |

10.11.2014

EN

Official Journal of the European Union

C 395/68

---

Order of the Civil Service Tribunal (3rd Chamber) of 30 September 2014 — Ojamaa v Parliament

(Case F-37/14) (1)

((Civil service - Officials - Appointing authority - Act adversely affecting an official - Manifest inadmissibility))

(2014/C 395/83)

Language of the case: French

Parties

Applicant: Priit Ojamaa (Brussels, Belgium) (represented by: M. Casado García-Hirschfeld, lawyer)

Defendant: European Parliament (represented by: M. Ecker and N. Chemaï, Agents)

Re:

Application for annulment of the Parliament’s decision not to allow 16 days of leave not taken in 2012 to be carried over to 2013, after the applicant had been on long-term sick leave for a serious illness.

Operative part of the order

| 1. | The action is dismissed as manifestly inadmissible. |
| --- | --- |

1.

The action is dismissed as manifestly inadmissible.

| 2. | Mr Ojamaa is to bear his own costs and is ordered to pay the costs incurred by the European Parliament. |
| --- | --- |

2.

Mr Ojamaa is to bear his own costs and is ordered to pay the costs incurred by the European Parliament.

---

(1)  OJ C 184 of 16/06/2014, p. 47.

---
# L_2019230DE.01001101.xml

| 6.9.2019 | DE | Amtsblatt der Europäischen Union | L 230/11 |
| --- | --- | --- | --- |

6.9.2019

DE

Amtsblatt der Europäischen Union

L 230/11

---

Berichtigung der Leitlinie (EU) 2019/1265 der Europäischen Zentralbank vom 10. Juli 2019 zum Euro Short-Term Rate (EURSTR) (EZB/2019/19)

(
  Amtsblatt der Europäischen Union L 199 vom 26. Juli 2019
  )

Auf der Umschlagseite sowie auf Seite 8, Titel der Leitlinie:

Anstatt:

„Leitlinie (EU) 2019/1265 der Europäischen Zentralbank vom 10. Juli 2019 zum Euro Short-Term Rate (EURSTR) (EZB/2019/19)“

muss es heißen:

„Leitlinie (EU) 2019/1265 der Europäischen Zentralbank vom 10. Juli 2019 zum Euro Short-Term Rate (€STR) (EZB/2019/19)“.

Seite 8, Erwägungsgrund 1 und Seite 10, Artikel 2:

Anstatt:

„(EURSTR)“

muss es heißen:

„(€STR)“.

---
###### Editorial Note on Part 178

#### Editorial Note:

Nomenclature changes to part 178 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 70 FR 72074, Dec. 1, 2005; and 81 FR 49896, July 29, 2016.

#### § 178.3760 Polyethylene glycol (400) monolaurate.

Polyethylene glycol (400) monolaurate containing not more than 0.1 percent by weight of ethylene and/or diethylene glycol may be used at a level not to exceed 0.3 percent by weight of twine as a finish on twine to be used for tying meat provided the twine fibers are produced from nylon resins complying with § 177.1500 of this chapter.
<TABLE> <S> <C>

<ARTICLE> 5
<CIK> 0000814070
<NAME> DRY DAIRY INTERNATIONAL INC
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-END>                               SEP-30-1997
<CASH>                                               0
<SECURITIES>                                         0
<RECEIVABLES>                                  192,341
<ALLOWANCES>                                         0
<INVENTORY>                                    101,571
<CURRENT-ASSETS>                               307,852
<PP&E>                                         632,481
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                 940,333
<CURRENT-LIABILITIES>                          322,491
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                     2,473,093
<OTHER-SE>                                 (2,017,772)
<TOTAL-LIABILITY-AND-EQUITY>                   940,333
<SALES>                                        939,325
<TOTAL-REVENUES>                               939,325
<CGS>                                          771,759
<TOTAL-COSTS>                                  632,104
<OTHER-EXPENSES>                               (4,288)
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                            (12,632)
<INCOME-PRETAX>                              (481,458)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (481,458)
<EPS-PRIMARY>                                   (0.01)
<EPS-DILUTED>                                   (0.01)
        

</TABLE>
132 STAT. 4374 PUBLIC LAW 115–290—DEC. 6, 2018 

LEGISLATIVE HISTORY—H.R. 4960: 

CONGRESSIONAL RECORD, Vol. 164 (2018): 

July 16, considered and passed House. 

Nov. 15, considered and passed Senate. 

Æ 

Public Law 115–290 

115th Congress 

An Act 

To designate the facility of the United States Postal Service located at 511 East 

Walnut Street in Columbia, Missouri, as the ‘‘Spc. Sterling William Wyatt Post 

Office Building’’. 

Be it enacted by the Senate and House of Representatives of 

the United States of America in Congress assembled, 

SECTION 1. SPC. STERLING WILLIAM WYATT POST OFFICE BUILDING. 

(a) DESIGNATION.—The facility of the United States Postal 

Service located at 511 East Walnut Street in Columbia, Missouri, 

shall be known and designated as the ‘‘Spc. Sterling William Wyatt 

Post Office Building’’. 

(b) REFERENCES.—Any reference in a law, map, regulation, 

document, paper, or other record of the United States to the facility 

referred to in subsection (a) shall be deemed to be a reference 

to the ‘‘Spc. Sterling William Wyatt Post Office Building’’. 

Approved December 6, 2018. 

Dec. 6, 2018 

[H.R. 4960] 


ralbany on LAP520R082 with PUB LAWS PDF
Exhibit 23

Consent of Independent Registered Public Accounting Firm

The
Board of Directors
Ballantyne of Omaha, Inc.:

We
consent to the incorporation by reference in the registration statements on Forms S-8 (File Nos. 333-03849, 333-116739,
333-139177, and 333-153408) of Ballantyne of Omaha, Inc. of our report dated March 16, 2009, except as to Note 27, which is as of March 27, 2009,
with respect to the consolidated balance sheets of Ballantyne of Omaha, Inc. and subsidiaries as of December 31, 2008 and 2007, and the related consolidated statements of operations,
stockholders' equity and comprehensive income (loss), and cash flows for each of the years in the three-year period ended December 31, 2008, and the related financial statement
schedule II, and our report dated March 16, 2009 with respect to the effectiveness of Ballantyne of Omaha, Inc.'s internal control over financial reporting as of December 31,
2008, which reports appear in the December 31, 2008 annual report on Form 10-K/A of Ballantyne of Omaha, Inc.

Our
report dated March 16, 2009, except as to Note 27, which is as of March 27, 2009, on the consolidated balance sheets of Ballantyne of Omaha, Inc. and
subsidiaries as of December 31, 2008 and
2007, and the related consolidated statements of operations, stockholders' equity and comprehensive income (loss), and cash flows for each of the years in the three-year period ended
December 31, 2008, and the related financial statement schedule II, refers to Ballantyne of Omaha, Inc.'s adoption of the fair value method of accounting for stock-based
compensation as required by Statement of Financial Accounting Standards No. 123(R),Share-Based Payment, on January 1, 2006 and the
adoption of the recognition and disclosure provisions of Statement of Financial Accounting Standards No. 158,Employer's Accounting for Defined Benefit Pension and Other
Postretirement Plans, as of December 31, 2006.

KPMG
LLP

Omaha,
Nebraska
March 27, 2009

---



QuickLinks
§ 522.1696b Penicillin G procaine aqueous suspension. ( a ) *Specifications.* Each milliliter contains penicillin G procaine equivalent to 300,000 units of penicillin G.
( b ) *Sponsors.* See sponsor numbers in § 510.600(c) of this chapter as follows: ( 1 ) Nos. 016592 and 054771 for use as in paragraph (d) of this section.
( 2 ) Nos. 055529 and 061133 for use as in paragraph (d)(2) of this section.
( c ) *Related tolerances.* See § 556.510 of this chapter.
( d ) *Conditions of use* — ( 1 ) *Dogs and cats* — ( i ) *Amount.* 10,000 units per pound body weight daily by intramuscular injection.
( ii ) *Indications for use.* Treatment of infections caused by penicillin-sensitive organisms.
( iii ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( 2 ) *Cattle, sheep, swine, and horses* — ( i ) *Amount.* 3,000 units per pound body weight (1 milliliter per 100 pounds body weight) daily by intramuscular injection.
( ii ) *Indications for use.* Treatment of cattle and sheep for bacterial pneumonia (shipping fever) caused by *Pasteurella multocida*; swine for erysipelas caused by *Erysipelothrix rhusiopathiae*; and horses for strangles caused by *Streptococcus equi.*
( iii ) *Limitations.* Not for use in horses intended for food. Milk that has been taken during treatment and for 48 hours after the last treatment must not be used for food. ( A ) For Nos. 054771 and 061133: Do not exceed 7 days of treatment in nonlactating dairy and beef cattle, sheep, and swine, or 5 days in lactating cattle. Discontinue treatment for the following number of days before slaughter: Nonruminating cattle (calves)—7; all other cattle—4; sheep—8; and swine—6.
( B ) For Nos. 016592 and 055529: Treatment should not exceed 4 consecutive days. A withdrawal period has not been established for this product in pre-ruminating calves. Discontinue treatment for the following number of days before slaughter: Cattle—10; sheep—9; and swine—7.
( C ) Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[66 FR 712, Jan. 4, 2001, as amended at 68 FR 34534, June 10, 2003; 68 FR 42589, July 18, 2003; 69 FR 17586, Apr. 5, 2004; 70 FR 16935, Apr. 4, 2005; 73 FR 14177, Mar. 17, 2008; 75 FR 54017, Sept. 3, 2010; 78 FR 17597, Mar. 22, 2013; 79 FR 16192, Mar. 25, 2014; 81 FR 22524, Apr. 18, 2016; 84 FR 8974, Mar. 13, 2019; 85 FR 18120, Apr. 1, 2020; 88 FR 14899, Mar. 10, 2023; 88 FR 16548, Mar. 20, 2023; 88 FR 27700, May 3, 2023]
NOT FOR PUBLICATION

UNITED STATES COURT OF APPEALS

FOR THE NINTH CIRCUIT

RAYMOND A. ROLES, 

Plaintiff-Appellant, 

 v. 

JAY CHRISTENSEN, ISCC Warden; 

RHONDA OWENS, ISCC, ASM, 

Defendants-Appellees.

No. 20-35071 

D.C. No. 1:19-cv-00292-DCN 

MEMORANDUM*

Appeal from the United States District Court

for the District of Idaho

David C. Nye, District Judge, Presiding

Submitted December 2, 2020**

Before: WALLACE, CLIFTON, and BRESS, Circuit Judges.

Idaho state prisoner Raymond A. Roles appeals pro se from the district 

court’s judgment dismissing his action brought under 42 U.S.C. § 1983 and the 

Religious Land Use and Institutionalized Persons Act (“RLUIPA”). We have 

jurisdiction under 28 U.S.C. § 1291. We review de novo. Watison v. Carter, 668 

* This disposition is not appropriate for publication and is not precedent 

except as provided by Ninth Circuit Rule 36-3.

** The panel unanimously concludes this case is suitable for decision 

without oral argument. See Fed. R. App. P. 34(a)(2).

FILED

DEC 10 2020

MOLLY C. DWYER, CLERK

U.S. COURT OF APPEALS
2 20-35071 

F.3d 1108, 1112 (9th Cir. 2012) (dismissal under 28 U.S.C. § 1915(e)(2)(B)(ii)); 

Resnick v. Hayes, 213 F.3d 443, 447 (9th Cir. 2000) (dismissal under 28 U.S.C. 

§ 1915A). We affirm.

The district court properly dismissed Roles’s action because Roles failed to 

allege facts sufficient to show that defendants’ conduct placed a substantial burden 

on his religious exercise. See Jones v. Williams, 791 F.3d 1023, 1031-32 (9th Cir. 

2015) (elements of § 1983 free exercise claim); Walker v. Beard, 789 F.3d 1125, 

1134 (9th Cir. 2015) (elements of a RLUIPA claim); San Jose Christian Coll. v. 

City of Morgan Hill, 360 F.3d 1024, 1034 (9th Cir. 2004) (under RLUIPA, to 

constitute a substantial burden on religious exercise, a regulation “must impose a 

significantly great restriction or onus upon such exercise”).

AFFIRMED.
Aero Air, LLC.

Portland

- Hillsboro Airport
2050 NE 25 th Avenue Hillsboro, OR 97124
Ph: 503.640.3711
Fax: 503.640.1093
www.aeroair.com

December 16, 2016

Docket Management Facility US Department of Transportation
12 00 New Jersey Avenue, SE West Building Ground Floor
Room W12

- 140 Washington, DC 20590

Exemption No. 11719, Regulatory Docket No. FAA

- 2015

- 0098

Dear Sir / Mam:

Aero Air, LLC, the parent company of Corsair Two, LLC, requested and received exemption 1 1719, Regulatory Docket No. FAA

- 2015

- 0098 to allow Aero Air to conduct flights without a flight engineer as required per CFR 91.529(a) (1) on its DC

- 7/DC

- 7B aircraft (registration Nos. N401US, N6353C, and N838D). This exemption is currently set to expire on May 31, 2017. Aero Air requests that this exemption be renewed beginning May 1, 2017 in order to facilitate the use of this exemption during the 2017 fire season and beyond without interruption. Not having this exemption in place could place undue tim e constraints on locating and training appropriate personnel in order to be available for the 2017 firefighting season. The conditions and reasons regarding public interest and safety for this exception remain unchanged for the previous submittal.

If a f light engineer were to be mandated their services would be needed for only two or three weeks each year and there is no way he could maintain the currency requirements, so an annual flight check would be required. This would create an economic burden that would be detrimental to the costs passed to the customer/taxpayer.

Granting this request would be in the public interest because our services are paid for by taxes through public agencies. If we can keep our costs at a minimum, we can provide service at a lower cost to the
government. We would appreciate prompt consideration of this request to allow our transition into spring training as we complete the annual maintenance on the aircraft.

Please contact me at Aero Air should you have any additional que stions or concerns.

Sincerely,

Kevin Mcloughlin Director of Production/Air Tanker Operations

Aero Air LLC
§ 54.5 Agency evaluation of financial interests. ( a ) *Evaluation of disclosure statement.* FDA will evaluate the information disclosed under § 54.4(a)(2) about each covered clinical study in an application to determine the impact of any disclosed financial interests on the reliability of the study. FDA may consider both the size and nature of a disclosed financial interest (including the potential increase in the value of the interest if the product is approved) and steps that have been taken to minimize the potential for bias.
( b ) *Effect of study design.* In assessing the potential of an investigator's financial interests to bias a study, FDA will take into account the design and purpose of the study. Study designs that utilize such approaches as multiple investigators (most of whom do not have a disclosable interest), blinding, objective endpoints, or measurement of endpoints by someone other than the investigator may adequately protect against any bias created by a disclosable financial interest.
( c ) *Agency actions to ensure reliability of data.* If FDA determines that the financial interests of any clinical investigator raise a serious question about the integrity of the data, FDA will take any action it deems necessary to ensure the reliability of the data including: ( 1 ) Initiating agency audits of the data derived from the clinical investigator in question;
( 2 ) Requesting that the applicant submit further analyses of data, e.g., to evaluate the effect of the clinical investigator's data on overall study outcome;
( 3 ) Requesting that the applicant conduct additional independent studies to confirm the results of the questioned study; and
( 4 ) Refusing to treat the covered clinical study as providing data that can be the basis for an agency action.
§ 582.5933 Vitamin A acetate. ( a ) *Product.* Vitamin A acetate.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
§ 114.5 Current good manufacturing practice. The criteria in §§ 114.10, 114.80, 114.83, 114.89, and 114.100, as well as the criteria in parts 110 and 117 of this chapter, apply in determining whether an article of acidified food is adulterated: ( a ) Within the meaning of section 402(a)(3) of the Federal Food, Drug, and Cosmetic Act in that it has been manufactured under such conditions that it is unfit for food; or
( b ) Within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act in that it has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth, or whereby it may have been rendered injurious to health.
[80 FR 56144, Sept. 17, 2015]
EXHIBIT 32 -- CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

This certification is provided pursuant to Section 906 of the Sarbanes-Oxley Act
of 2002 and accompanies the Quarterly Report on Form 10-Q, as amended (the "Form
10-Q"), for the quarter ended March 31, 2006 of Crimson Exploration Inc. (the
"Issuer"). The undersigned, the President and Chief Executive Officer of the
Issuer and the Senior Vice President and Chief Financial Officer of the Issuer,
hereby certify that the Form 10-Q fully complies with the requirements of
Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (15 U.S.C.
78m or 78o(d)) and that the information contained in the Form 10-Q fairly
presents, in all material respects, the financial condition and results of
operations of the Issuer.



Dated: July 17, 2006

By:   /s/ Allan D. Keel
    ---------------------------
Name:     Allan D. Keel
Title:    President and Chief Executive Officer


By:   /s/ E. Joseph Grady
    ---------------------------
Name:     E. Joseph Grady
Title:    Senior Vice President and Chief Financial Officer


A signed original of this written statement required by Section 906 has been
provided to the Issuer and will be furnished to the Securities and Exchange
Commission, or its staff, upon request.
EXHIBIT 32.1
Exhibit 32.1
                CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
                    AS ADOPTED PURSUANT TO SECTION 906 OF THE
                           SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Avitar, Inc. (the "Company") on
Form10-QSB for the period ending June 30, 2003 as filed with the Securities and
Exchange Commission on the date hereof (the "Report"), I, Peter P. Phildius,
Chief Executive Officer of the Company certify, pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to
my knowledge, that:

     (1) The Report fully complies with the requirements of Section 13(a)
or15(d) of the Securities Exchange Act of 1934; and

     (2) The information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the
Company.

Date: August 13, 2003

                                                  /s/ Peter P. Phildius
                                                  ---------------------
                                                  Peter P. Phildius Chief
                                                  Executive Officer
# C_2014431EN.01001502.xml

| 1.12.2014 | EN | Official Journal of the European Union | C 431/15 |
| --- | --- | --- | --- |

1.12.2014

EN

Official Journal of the European Union

C 431/15

---

Request for a preliminary ruling from the Conseil de prud’hommes de Paris (France) lodged on 22 September 2014 — David Van der Vlist v Bio Philippe Auguste SARL

(Case C-432/14)

(2014/C 431/22)

Language of the case: French

Referring court

Referring court

Conseil de prud’hommes de Paris

Parties to the main proceedings

Parties to the main proceedings

Applicant: David Van der Vlist

Applicant:

Defendant: Bio Philippe Auguste SARL

Defendant:

Question referred

Question referred

Does the general principle of non-discrimination on grounds of age preclude national legislation (Article L. 1243-10 of the French Code du travail) which excludes young persons who work during their school holidays or university vacations from entitlement to an insecurity payment payable in the event that employment under a fixed-term contract is not followed by an offer of permanent employment?

---
IN THE SUPREME COURT OF PENNSYLVANIA

WESTERN DISTRICT

JENNIFER M. STRAW AND THOMAS P. STRAW, INDIVIDUALLY AND AS CO

ADMINISTRATORS OF THE ESTATE OF ELIJAH C. STRAW, DECEASED; AND ROWAN J. STRAW, A MINOR, BY AND

THROUGH HIS PARENTS AND NATURAL GUARDIANS, JENNIFER M.

STRAW AND THOMAS P. STRAW.

v.

KIRK A. FAIR AND GOLON MASONRY RESTORATION, INC.

v.

PITTSBURGH LUBES, INC. D/B/A JIFFY LUBE, TOWER AUTO SALES & SERVICE, NATIONAL AUTOMOTIVE

PARTS ASSOCIATION

- NAPA AUTO

PARTS T/D/B/A NAPA

v.

THOM AS P. STRAW

PETITION OF: TOWER AUTO SALES &

SERVICE AND JOHN R. FANTO :

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

: No. 322 WAL 2018

Petition for Allowance of Appeal from the Order of the Superior Court

JENNIFER M. STRAW AND THOMAS P. STRAW, INDIVIDUALLY AND AS CO

ADMINISTRATORS OF THE ESTATE OF ELIJAH C. STRAW, DECEASED; AND ROWAN J. STRAW, A MINOR, BY AND

THROUGH HIS PARENTS AND :

:

:

:

:

: No. 323 WAL 2018

Petition for Allowance of Appeal from the Order of the Superior Court[ 322 WAL 2018 and 323 WAL 2018 ]

- 2

NATURAL GUARDIANS, JENNIFER M.

STRAW AND THOMAS P. STRAW

v.

KIRK A. F AIR AND GOLON MASONRY RESTORATION, INC.

v.

PITTSBURGH LUBES, INC. D/B/A JIFFY LUBE, TOWER AUTO SALES & SERVICE, NATIONAL AUTOMOTIVE

PARTS ASSOCIATION

- NAPA AUTO

PARTS T/D/B/A NAPA

v.

THOMAS P. STRAW

PETITION OF: TOWER AUTO SALES &

SERVICE AND JOHN R. FANTO :

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

ORDER

PER CURIAM

AND NOW , this 15th day of February, 2019

, the Petition for Allowance of Appeal

is DENIED

.
# L_2019330EN.01010501.xml

| 20.12.2019 | EN | Official Journal of the European Union | L 330/105 |
| --- | --- | --- | --- |

20.12.2019

EN

Official Journal of the European Union

L 330/105

---

Corrigendum to Decision (EU) 2019/2158 of the European Central Bank of 5 December 2019 on the methodology and procedures for the determination and collection of data regarding fee factors used to calculate annual supervisory fees (ECB/2019/38)

(Official Journal of the European Union L 327 of 17 December 2019)

On page 104, Article 11:

for:

‘This Decision shall enter into force on the third day following that of its publication in the Official Journal of the European Union.’,

read:

‘This Decision shall enter into force on 1 January 2020.’

---
§ 582.5950 Vitamin D2. ( a ) *Product.* Vitamin D2.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
#### § 71.18 Petition for exemption from certification.

A manufacturer, packer, or distributor of a color additive or color additive mixture may petition for an exemption from certification pursuant to part 10 of this chapter. Any such petition shall show why such certification is not necessary for the protection of public health.